Boston Scientific (NYSE:BSX) is reportedly still considering a market withdrawal in India for its Synergy adsorbable polymer stent, after repeated attempts to lift a government-imposed price cap were rebuffed by regulators there. Representatives from the Marlborough, Mass.-based medical device giant met yesterday with National Pharmaceutical Pricing Authority officials to discuss pulling Synergy from India, according to LiveMint. […]
Micell raises $62m for MiStent SES
Micell Technologies said last week that it raised a debt-and-equity round worth nearly $62 million from a syndicate of 51 unnamed investors. Paris-based Micell makes the MiStent SES sirolimus-eluting absorbable polymer coronary stent, designed to treat coronary artery disease. The company, which reported a nearly $26 million round last November, said in a regulatory filing that the […]
Senseonics wins CE Mark for Eversense XL glucose monitor
Senseonics (NYSE:SENS) said yesterday that it won CE Mark approval in the European Union for its Eversense XL continuous glucose monitor. The Eversense XL includes a glucose sensor designed to be implanted for 180 days and a removable smart transmitter that links with a mobile app for real-time glucose monitoring. Germantown, Md.-based Senseonics touts the sensor […]
Medtronic recalls insulin infusion sets
Medtronic (NYSE:MDT) said today that it’s recalling some of the infusion sets used with its insulin pumps due to problems with a discontinued component. The Fridley, Minn.-based medical device titan said the problem involves a vent membrane that’s susceptible to blockage during priming and fill-tubing. No pumps or glucose sensors are affected by the recall, Medtronic […]
Insulet breaks ground on new manufacturing plant in Mass.
Insulet (NSDQ:PODD) reportedly broke ground on a new manufacturing facility on a site it bought earlier this year in Acton, Mass. The $100 million, 350,000-square foot plant is being built on a 26-acre lot Billerica, Mass.-based Insulet acquired for $9.3 million in February, according to the Worcester Business Journal. Insulet uses a quarter of contract manufacturers to make […]
Medtronic supply woes buoy insulin device makers
Share prices for makers of insulin management devices got a bump today after Medtronic (NYSE:MDT) reported today that supply problems pushed sales down -1% for its diabetes division. The Fridley, Minn.-based company, which released its fiscal 2018 first-quarter results this morning, posted diabetes revenues of $449 million for the three months ended July 28. The decline was […]
Medtronic launches DAPT study for Resolute Onyx DES
Medtronic (NYSE:MDT) said today that it’s launching a study of dual anti-platelet therapy and its Resolute Onyx drug-eluting stent. The 2,000-patient study is designed to compare a one-month course of aspirin and an anti-coagulant in conjunction with the Resolute Onyx device or the BioFreedom DES made by Biosensors International (PINK:BSNRY). The Resolute Onyx stent is made […]
Roche’s prospects clouded by clinical flops
(Reuters) — A run of disappointing drug trials at Roche (OTC:RHHBY) has left analysts suggesting the view from its new 41-story office building in Basel has become more clouded, with little chance of management now upgrading its growth forecast next week, when it reports first-half earnings. Moreover, the first of a threatened flood of biosimilar […]
Tusker Medical raises $10m for pediatric tympanostomy device
Tusker Medical said yesterday that it raised more than $10 million for the pediatric ear surgery device it’s developing. The Menlo Park, Calif.-based company raised $10.2 million in an equity sale from a single unnamed investor, according to a regulatory filing. Tusker, formerly known as Advanced ENT Solutions, is developing a new technique for tympanostomies, in […]
BoneSupport readies $62m IPO
BoneSupport said this week that it’s planning to float an initial public offering that would fetch roughly $62 million at the midpoint, not including an over-allotment option. The Swedish company, which is developing the Cerament G injectable antibiotic-eluting bone graft substitute, said it plans to offer more than 18.5 million shares at $3.13 to $3.59 apiece […]
